AGP
AMLX icon

Artia Global Partners’s Amylyx Pharmaceuticals AMLX Stock Holding History

Artia Global Partners’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-8,339
Closed -$245K – 36
2023
Q1 		$245K Sell
8,339
-15,544
-65% -$540K 0.09% 34
2022
Q4 		$882K Buy
+23,883
New +$848K 0.34% 24

Other funds holding AMLX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Artia Global Partners's AMLX Position: Q2 2023 in Review

Artia Global Partners sold out of Amylyx Pharmaceuticals (AMLX) in Q2 2023, closing a stake of 8,339 shares — an estimated $245K sold.

Artia Global Partners first reported a position in AMLX in Q4 2022 and held it in 2 quarters. The position peaked at $882K in Q4 2022. 154 funds tracked by Wall St. Rank hold AMLX as of Q2 2023.

  • Artia Global Partners reported no remaining Amylyx Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Artia Global Partners sold 8,339 Amylyx Pharmaceuticals shares in Q2 2023, an estimated $245K.
  • Artia Global Partners first reported a position in Amylyx Pharmaceuticals in Q4 2022 and held it in 2 quarters.
  • Artia Global Partners's Amylyx Pharmaceuticals position peaked at $882K in Q4 2022.
  • 154 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2023.

Based on Artia Global Partners's 13F filing for Q2 2023, filed 14 Aug 2023.